Sonnet BioTherapeutics Holdings, Inc. (SONN)

NASDAQ: SONN · Real-Time Price · USD
1.000
+0.049 (5.15%)
At close: Sep 18, 2024, 4:00 PM
0.969
-0.031 (-3.10%)
After-hours: Sep 18, 2024, 6:11 PM EDT
5.15%
Market Cap 5.20M
Revenue (ttm) 55,881
Net Income (ttm) -7.99M
Shares Out 5.20M
EPS (ttm) -2.10
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 157,418
Open 0.997
Previous Close 0.951
Day's Range 0.905 - 1.030
52-Week Range 0.620 - 3.460
Beta 0.99
Analysts Strong Buy
Price Target 14.67 (+1,367.0%)
Earnings Date Aug 14, 2024

About SONN

Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Pankaj Mohan
Employees 12
Stock Exchange NASDAQ
Ticker Symbol SONN
Full Company Profile

Financial Performance

In 2023, SONN's revenue was $147,805, a decrease of -57.76% compared to the previous year's $349,943. Losses were -$18.83 million, -36.64% less than in 2022.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for SONN stock is "Strong Buy." The 12-month stock price forecast is $14.67, which is an increase of 1,367.00% from the latest price.

Price Target
$14.67
(1,367.00% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors

SON-1010 is a targeted immune activation cancer therapy designed to turn ‘cold' tumors ‘hot' Topline safety data of SB101 Phase 1 study expected by Q4 2024 PRINCETON, NJ, Sept. 18, 2024 (GLOBE NEWSWIR...

13 hours ago - GlobeNewsWire

Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell Series

PRINCETON, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic dru...

14 days ago - GlobeNewsWire

Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer

Preclinical data has demonstrated the potential of SON-1210, the first albumin-binding bifunctional IL-12/IL-15 fusion protein, for solid tumor immunotherapy

4 weeks ago - GlobeNewsWire

Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

Ongoing progress with both clinical trials of lead program, SON-1010, for solid tumors and Platinum-Resistant Ovarian Cancer (PROC)

5 weeks ago - GlobeNewsWire

Sonnet BioTherapeutics (NASDAQ:SONN) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team

Watch the "What This Means" segment here FRENCHTOWN, NJ / ACCESSWIRE / July 24, 2024 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today released a Virtu...

2 months ago - Accesswire

Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 Study

PRINCETON, N.J., July 24, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs...

2 months ago - GlobeNewsWire

Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting

PRINCETON, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic d...

4 months ago - GlobeNewsWire

Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target

The SON-1010 studies have together enrolled 61 subjects, to date, as dose escalation continues in SB101 and SB221 at higher levels Patients have received up to 25 cycles of SON-1010 as monotherapy and...

4 months ago - Accesswire

Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update

Published Phase 1 data of SON-1010 in Frontiers in Immunology demonstrating the safety and tolerability of the F H AB-derived Interleukin 12 in healthy volunteers Announced early safety data from the ...

4 months ago - Accesswire

Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference

PRINCETON, NJ / ACCESSWIRE / May 6, 2024 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a biopharmaceutical company developing innovative targeted biologic drugs, will be participating in the ...

4 months ago - Accesswire

Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting

PRINCETON, NJ / ACCESSWIRE / March 19, 2024 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs...

6 months ago - Accesswire

Sonnet BioTherapeutics Announces Early Safety Data from the Company's Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study's Initial Pre-Specified Objective

Safety in the Phase 1b part of Sonnet's double-blind, randomized, controlled trial of SON‑080 was reviewed by the study's Data Safety Monitoring Board (DSMB) The adverse event profile and tolerability...

6 months ago - Accesswire

Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers

PRINCETON, NJ / ACCESSWIRE / February 29, 2024 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs for cancer, announced today t...

7 months ago - Accesswire

Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update

Successfully raised approximately $4.55 million in gross proceeds through an underwritten public offering Extensive preclinical data on SON-1210 published in Frontiers in Immunology Received approval ...

7 months ago - Accesswire

Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy

PRINCETON, NJ / ACCESSWIRE / December 21, 2023 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs for cancer, announced today t...

9 months ago - Accesswire

Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update

PRINCETON, NJ / ACCESSWIRE / December 14, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic dr...

9 months ago - Accesswire

Sonnet BioTherapeutics Provides Fiscal Year 2023 Business Overview

Following the recent completion of a $4.55 million financing, Sonnet projects cash runway into the calendar year third quarter of 2024 The company is focused on its business development initiatives an...

11 months ago - Accesswire

Sonnet BioTherapeutics Announces Pricing of $4.55 Million Underwritten Public Offering

PRINCETON, NJ / ACCESSWIRE / October 25, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("we," "us," "our," "Sonnet" or the "Company"), a clinical-stage company developing innovative targe...

11 months ago - Accesswire

Sonnet BioTherapeutics Announces Abstract Accepted for Presentation by a Key Opinion Leader at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting

PRINCETON, NJ / ACCESSWIRE / October 17, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic dru...

1 year ago - Accesswire

Sonnet BioTherapeutics Announces Results of Biodistribution Studies Demonstrating Solid Tumor Targeting Using the FHAB Technology

Two independent radiolabeling studies showed a 2.5- to 4.7-fold increase in tumor tissue with mIL12-FHAB, the mouse version of SON‑1010, compared with mIL-12 alone Accumulation was observed in tumors ...

1 year ago - Accesswire

Sonnet BioTherapeutics Regains Nasdaq Minimum Bid Price Compliance

PRINCETON, NJ / ACCESSWIRE / September 19, 2023 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that it has...

1 year ago - Accesswire

Sonnet BioTherapeutics Announces 1-for-22 Reverse Stock Split

PRINCETON, NJ / ACCESSWIRE / August 31, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drug...

1 year ago - Accesswire

Sonnet BioTherapeutics Announces FDA Acceptance of the Company's IND for the SB221 Clinical Trial of SON-1010 Combined with Atezolizumab in the US

An IND was required to conduct the SB221 study of platinum-resistant ovarian cancer (PROC) with the combination of Sonnet's SON-1010 and Roche's atezolizumab (Tecentriq ®) in the US As part of the ov...

1 year ago - Accesswire

Sonnet BioTherapeutics Provides Fiscal Year 2023 Third Quarter Business and Earnings Update

Combination study of SON-1010 with Roche's atezolizumab (Tecentriq®) has been initiated in Australia First SON-1010 Phase 1 study has been completed and comparison of the human pharmacokinetic data su...

1 year ago - Accesswire

Sonnet BioTherapeutics to Present at the 2023 BTIG Virtual Biotechnology Conference

PRINCETON, NJ / ACCESSWIRE / July 31, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs,...

1 year ago - Accesswire